Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine is under clinical development by Vaxart and currently in Phase II for Norovirus Infections. According to GlobalData, Phase II drugs for Norovirus Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine overview

The vaccine candidate is under development for the prevention of norovirus gastroenteritis. It is a bivalent adenovirus type 5 vector based vaccine consisting of norovirus GI.1 Norwalk strain and norovirus GII.4 Sydney strain. The vaccine candidate is formulated as the enteric-coated tablet for oral administration. It is developed based on vector-adjuvant-antigen standardized technology (VAAST) platform.

Vaxart overview

Vaxart, formerly Aviragen Therapeutics, is a clinical-stage pharmaceutical company that develops oral recombinant vaccines based on its proprietary oral vaccine platform, using state-of-the-art recombinant technology. The platform enables the company to develop oral versions of currently available vaccines, and design recombinant vaccines for new indications. The company is developing prophylactic vaccine candidates for a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. It is also developing a therapeutic immune-oncology vaccine, which targets cervical cancer and dysplasia caused by human papilloma virus (HPV). Vaxart is headquartered in San Francisco, California, the US.

For a complete picture of Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.